Carcinoma, Hepatocellular  >>  TheraSphere (yttrium 90 microspheres)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TheraSphere (yttrium 90 microspheres) / Boston Scientific
NCT00039078: Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery

Withdrawn
2
0
US
yttrium Y 90 glass microspheres
Allan Tsung
Liver Cancer
08/00
08/00
NCT00910572: Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced Hepatocellular Carcinoma

Completed
2
60
Europe
Yttrium-90 microspheres (Therasphere MDS Nordion), Therasphere, produced by MDS Nordion, Ottawa, Canada
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Gastro Intestinal Surgery and Liver Transplantation, The Hepato-Oncology Group: Department of Surgery, Medicine and Radiology
Hepatocellular Carcinoma, Liver Cancer
11/09
05/10
NCT02582034: Internal Radiation Therapy for Hepatocellular Carcinomas With Therasphere: Optimized Dosimetry Versus Standard Dosimetry

Completed
2
56
Europe
Optimized Internal Radiation Therapy, Standard Internal Radiation Therapy
Center Eugene Marquis
Adenoma, Liver Cell
12/18
12/18
NCT00493883: Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors

Completed
1/2
81
US
yttrium Y 90 microspheres (TheraSphere®)
Southwestern Regional Medical Center
Carcinoma, Hepatocellular, Liver Neoplasms
12/11
12/11

Download Options